Ploumen, Eline H.
Pinxterhuis, Tineke H.
Zocca, Paolo
Roguin, Ariel
Anthonio, Rutger L.
Schotborgh, Carl E.
Benit, Edouard
Aminian, Adel
Danse, Peter W.
Doggen, Carine J. M.
von Birgelen, Clemens
Kok, Marlies M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials
https://doi.org/10.1186/s12933-021-01405-4
Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): Rationale and study design of the randomized TWENTE III multicenter trial
https://doi.org/10.1016/j.ahj.2013.11.014
Documents that mention this clinical trial
Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials
https://doi.org/10.1186/s12933-021-01405-4
Funding for this research was provided by:
Biotronik (Biotronik)
Boston Scientific Corporation (Boston Scientific Corporation)
Medtronic (Medtronic)
Article History
Received: 2 September 2021
Accepted: 14 October 2021
First Online: 30 October 2021
Declarations
:
: The trials complied with the Declaration of Helsinki and were approved by the Medical Ethics Committee Twente (BIO-RESORT reference number P12-22; BIONYX reference number P15-19) and the Institutional Review Boards of all centers. All patients provided written informed consent.
: Not applicable.
: CvB reports that the research department of Thoraxcentrum Twente has received institutional research grants provided by Abbott Vascular, Biotronik, Boston Scientific, and Medtronic. RLA reports a teaching grant from Biotronic, a lincense from Sanovi, a speaking fee from Abiomed and support from Amgen for attending a meeting, all outside the submitted work. All other authors declared that they have no potential conflict of interest.